PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ANI Pharmaceuticals, Inc. (ANIP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00182C1036
CUSIP00182C103
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$1.29B
EPS$1.61
PE Ratio38.09
PEG Ratio1.06
Revenue (TTM)$517.46M
Gross Profit (TTM)$177.60M
EBITDA (TTM)$112.38M
Year Range$44.27 - $70.81
Target Price$81.60
Short %1.42%
Short Ratio1.73

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ANI Pharmaceuticals, Inc.

Popular comparisons: ANIP vs. VOO, ANIP vs. COST, ANIP vs. FDX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ANI Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%December2024FebruaryMarchAprilMay
-78.84%
352.87%
ANIP (ANI Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ANI Pharmaceuticals, Inc. had a return of 14.67% year-to-date (YTD) and 37.01% in the last 12 months. Over the past 10 years, ANI Pharmaceuticals, Inc. had an annualized return of 7.11%, while the S&P 500 had an annualized return of 10.70%, indicating that ANI Pharmaceuticals, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date14.67%11.24%
1 month-3.26%4.04%
6 months25.66%16.49%
1 year37.01%26.17%
5 years (annualized)-1.38%13.76%
10 years (annualized)7.11%10.70%

Monthly Returns

The table below presents the monthly returns of ANIP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20241.23%21.23%2.16%-4.53%14.67%
202311.19%-6.46%-5.07%-5.04%19.67%19.25%-2.38%22.53%-9.83%6.34%-19.32%10.70%37.06%
2022-12.28%-7.35%-24.94%4.98%2.51%-1.92%15.44%7.71%-12.88%20.07%8.71%-4.10%-12.70%
2021-1.72%1.96%24.19%-7.91%3.22%2.04%-3.20%-10.61%8.21%13.89%10.06%12.01%58.68%
20200.54%-22.56%-15.14%-1.79%-22.37%4.12%-8.44%5.91%-10.04%-9.64%15.97%-1.76%-52.91%
201919.37%22.42%7.22%0.62%-1.86%18.00%2.91%-22.57%11.27%7.18%-21.11%0.08%36.98%
20184.20%-4.60%-9.13%1.94%6.64%5.55%0.22%-13.07%-2.85%-14.17%14.55%-19.01%-30.15%
2017-0.28%-2.28%-16.18%9.31%-19.27%7.12%4.12%-1.50%9.35%10.65%22.43%-9.37%6.32%
2016-29.06%3.28%1.81%35.09%19.09%3.08%8.56%-1.42%11.06%-10.02%-1.29%2.87%34.34%
2015-0.74%20.35%-7.14%-2.51%-17.38%23.16%14.47%-31.34%-18.99%5.90%4.73%2.98%-19.98%
201410.46%36.52%3.53%-0.77%2.38%8.13%-25.61%14.48%-3.58%20.08%59.33%4.21%180.83%
201313.01%-5.76%-10.69%-3.42%7.96%-18.03%15.67%2.31%37.61%4.91%39.02%40.91%172.09%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ANIP is 72, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of ANIP is 7272
ANIP (ANI Pharmaceuticals, Inc.)
The Sharpe Ratio Rank of ANIP is 7777Sharpe Ratio Rank
The Sortino Ratio Rank of ANIP is 7272Sortino Ratio Rank
The Omega Ratio Rank of ANIP is 7373Omega Ratio Rank
The Calmar Ratio Rank of ANIP is 6363Calmar Ratio Rank
The Martin Ratio Rank of ANIP is 7474Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ANIP
Sharpe ratio
The chart of Sharpe ratio for ANIP, currently valued at 1.11, compared to the broader market-2.00-1.000.001.002.003.004.001.11
Sortino ratio
The chart of Sortino ratio for ANIP, currently valued at 1.65, compared to the broader market-4.00-2.000.002.004.006.001.65
Omega ratio
The chart of Omega ratio for ANIP, currently valued at 1.23, compared to the broader market0.501.001.502.001.23
Calmar ratio
The chart of Calmar ratio for ANIP, currently valued at 0.42, compared to the broader market0.002.004.006.000.42
Martin ratio
The chart of Martin ratio for ANIP, currently valued at 3.48, compared to the broader market-10.000.0010.0020.0030.003.48
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.43, compared to the broader market-2.00-1.000.001.002.003.004.002.43
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.44, compared to the broader market-4.00-2.000.002.004.006.003.44
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.501.001.502.001.43
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.96, compared to the broader market0.002.004.006.001.96
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.23, compared to the broader market-10.000.0010.0020.0030.009.23

Sharpe Ratio

The current ANI Pharmaceuticals, Inc. Sharpe ratio is 1.11. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ANI Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.501.001.502.002.503.00December2024FebruaryMarchAprilMay
1.11
2.43
ANIP (ANI Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ANI Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-83.18%
-0.29%
ANIP (ANI Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ANI Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ANI Pharmaceuticals, Inc. was 98.57%, occurring on Jun 25, 2013. The portfolio has not yet recovered.

The current ANI Pharmaceuticals, Inc. drawdown is 83.18%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.57%Nov 30, 20042157Jun 25, 2013
-80.53%Aug 21, 2001320Apr 1, 2003348Sep 21, 2004668
-21.69%Jul 25, 20016Aug 1, 200111Aug 17, 200117
-14.12%Oct 8, 200420Nov 4, 200415Nov 26, 200435
-10.82%Sep 23, 20043Sep 27, 20046Oct 5, 20049

Volatility

Volatility Chart

The current ANI Pharmaceuticals, Inc. volatility is 7.78%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%December2024FebruaryMarchAprilMay
7.78%
3.00%
ANIP (ANI Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ANI Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items